Frank Booth made CMO as Sangart expands leadership team
This article was originally published in Scrip
Sangart, a privately-held biopharmaceutical company focused on oxygen-therapeutics agents, has appointed three new members to its executive team, including Frank Booth who has been named chief medical officer. Mr Booth has over 20 years' experience as a trauma and critical care surgeon and as a clinical investigator. Previously he worked in clinical development roles at Novo Nordisk and Lilly.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.